CATO Relative Valuation
CATO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CATO is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.27
P/B
Median3y
0.66
Median5y
0.82
-61.36
FCF Yield
Median3y
-12.67
Median5y
-7.75
Competitors Valuation Multiple
The average P/S ratio for CATO's competitors is 0.15, providing a benchmark for relative valuation. Cato Corp Corp (CATO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -9.71%, this premium appears unsustainable.
People Also Watch

PNNT
Pennantpark Investment Corp
6.410
USD
-1.69%

MITK
Mitek Systems Inc
8.100
USD
-2.17%

PACB
Pacific Biosciences of California Inc
1.110
USD
0.00%

ALNT
Allient Inc
21.630
USD
+1.31%

MYE
Myers Industries Inc
11.060
USD
+5.33%

ESPR
Esperion Therapeutics Inc
0.984
USD
-1.50%

CVRX
CVRx Inc
7.290
USD
-0.41%

HPP
Hudson Pacific Properties Inc
2.180
USD
+6.34%

SIGA
SIGA Technologies Inc
5.430
USD
-1.63%

AKBA
Akebia Therapeutics Inc
2.390
USD
-0.83%
FAQ

Is Cato Corp (CATO) currently overvalued or undervalued?
Cato Corp (CATO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Cato Corp (CATO) is between to according to relative valuation methord.

What is Cato Corp (CATO) fair value?

How does CATO's valuation metrics compare to the industry average?

What is the current P/B ratio for Cato Corp (CATO) as of May 02 2025?

What is the current FCF Yield for Cato Corp (CATO) as of May 02 2025?

What is the current Forward P/E ratio for Cato Corp (CATO) as of May 02 2025?
